Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 1 |
Small cell carcinoma | D018288 | — | — | 1 | 1 | — | — | — | 1 |
Small cell lung carcinoma | D055752 | — | — | 1 | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | 1 | 1 | — | — | — | 1 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | 1 | — | — | — | 1 |
Drug common name | Gilvetmab |
INN | gilvetmab |
Description | Gilvetmab is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3990007 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 949NG8376D (ChemIDplus, GSRS) |